De novo HBV infection in a Mayo Clinic hemodialysis population: Economic impact of reduced HBV testing and a call for changes in current US CDC guidelines on HBV testing protocols

Hemodialysis International

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Onuigbo, Macaulay A C ^a,b   Onuigbo, Nnonyelum T C ^c  

^a MAYO CLINIC   (United States)

^b Mayo Health System Practice Based Research Network MHS PBRN   (United States)

^c NTEC Solutions LLC   (United States)

Author keywords

Economic analysis; End stage renal disease; Gross domestic product; Hemodialysis; Hepatitis B virus infection; Medicare

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DISEASE CONTROL; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; DRUG USERS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84867178481     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00748.x     Document Type: Article

References (58)

1. Purcell RH. Hepatitis viruses: Changing patterns of human disease. Proc Natl Acad Sci U S A. 1994; 91:2401-2406.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev. 2006; 28:112-125. Epub 2006 Jun 5. Review.
3. Daniels D, Grytdal S, Wasley A. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ. 2009; 58:1-27.
4. Mast EE, Weinbaum CM, Fiore AE, etal. Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16):1-33. quiz CE1-4. Erratum in: MMWR Morb Mortal Wkly Rep. 2007 Oct 26;56(42):1114.
5. Weinbaum CM, Williams I, Mast EE, etal. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57(RR-8):1-20. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm (accessed date: September 24, 2010).
6. Centers for Disease Control and Prevention CDC. Division of Viral Hepatitis-Statistics and Surveillance. Atlanta, GA: US Department of Health and Human Services. Disease Burden from Viral Hepatitis A, B, and C in the United States. 2007; http://www.cdc.gov/hepatitis/pdfs/disease_burden.pdf (accessed date: September 23, 2010).
7. Garibaldi RA, Forrest JN, Bryan JA, Hanson BF, Dismukes WE. Hemodialysis-associated hepatitis. JAMA. 1973; 225:384-389.
8. London WT, Di Figlia M, Sutnick A, Blumberg BS. An epidemic of hepatitis in a chronic-hemodialysis unit. Australia antigen and differences in host response. N Engl J Med. 1969; 281:571-578.
9. Váry L, Karátson A, Köves S, Juhász J. Hepatitis and its problems in a haemodialysis Unit. Int Urol Nephrol. 1976; 8:257-264.
10. Cossart YE, Gillespie EH, Jones DM, Kelsey JC, etal. Infection risks of haemodialysis-some preventive aspects. A report to the Public Health Laboratory Service by the Working Party on Haemodialysis Units. Br Med J. 1968; 3:454-460.
11. Girndt M, Köhler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol. 2002; 22:340-350.
12. Snydman DR, Bryan JA, London WT, etal. Transmission of hepatitis B associated with hemodialysis: Role of malfunction (blood leaks) in dialysis machines. J Infect Dis. 1976; 134:562-570.
13. Snydman DR, Bryan JA, Macon EJ, Gregg MB. Hemodialysis-associated hepatitis: Report of an epidemic with further evidence on mechanisms of transmission. Am J Epidemiol. 1976; 104:563-570.
14. Alter MJ, Favero MS, Petersen NJ, Doto IL, Leger RT, Maynard JE. National surveillance of dialysis-associated hepatitis and other diseases: 1976 and 1980. Dial Transplant. 1983; 12:860-865.
15. Alter MJ, Favero MS, Maynard JE. Hepatitis B vaccine use in chronic hemodialysis centers in the United States. JAMA. 1985; 254:3200-3202.
16. Alter MJ, Favero MS, Maynard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis. 1986; 153:1149-1151.
17. Alter MJ, Favero MS, Miller JK, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1987. ASAIO Trans. 1989; 35:820-831.
18. Alter MJ, Favero MS, Miller JK, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1988. ASAIO Trans. 1990; 36:107-118.
19. Alter MJ, Favero MS, Miller JK, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the United States, 1989. ASAIO Trans. 1991; 37:97-109.
20. Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of hemodialysis associated diseases in the United States, 1990. ASAIO J. 1993; 39:71-80.
21. Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of dialysis associated diseases in the United States, 1991. ASAIO J. 1993; 39:966-975.
22. Tokars JI, Alter MJ, Favero MS, Moyer LA, Miller E, Bland LA. National surveillance of dialysis associated diseases in the United States, 1992. ASAIO J. 1994; 40:1020-1031.
23. Tokars JI, Alter MJ, Favero MS, Moyer LA, Miller E, Bland LA. National surveillance of dialysis associated diseases in the United States, 1993. ASAIO J. 1996; 42:219-229.
24. Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States, 1994. ASAIO J. 1997; 43:108-119.
25. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J. 1998; 44:98-107.
26. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National Surveillance of Dialysis-Associated Diseases in the United States, 1996. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC. 1998; 1-59.
27. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial. 2000; 13:75-85.
28. Centers for Disease Control and Prevention CDC. Hepatitis: Control Measures for Hepatitis B in Dialysis Centers. Atlanta, GA: US Department of Health, Education, and Welfare, Public Health Services, CDC. 1977. HEW publication no. (CDC) 78-8358 (Viral Hepatitis Investigations and Control Series).
29. Centers for Disease Control and Prevention (CDC). Recommendations of the Immunization Practices Advisory Committee (ACIP): Inactivated hepatitis B virus vaccine. MMWR. 1982; 31:317-322, 327-328.
30. Tokars JI. Description of a new surveillance system for bloodstream and vascular access infections in outpatient hemodialysis centers. Semin Dial. 2000; 13:97-100.
31. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001; 50(RR-5):1-43.
32. Centers for Disease Control and Prevention (CDC). 2008 Viral Hepatitis Scientific Information-Specific Settings. Hemodialysis and Viral Hepatitis. http://www.cdc.gov/hepatitis/settings/hemo.htm (accessed date: September 24, 2010).
33. Centers for Disease Control and Prevention (CDC). 2006 Guidelines for Vaccinating Kidney Dialysis Patients and Patients with Chronic Kidney Disease http://www.cdc.gov/vaccines/pubs/downloads/b_dialysis_guide-508.pdf (accessed date: September 24, 2010).
34. Centers for Disease Control and Prevention (CDC). Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. MMWR Morb Mortal Wkly Rep. 2008; 57:875-876.
35. Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ. 2009; 58:1-27.
36. Longworth DL. Accountable care organizations, the patient-centered medical home, and health care reform: What does it all mean? Cleve Clin J Med. 2011; 78:571-582.
37. The Concord Coalition. Escalating Health Care Costs and the Federal Budget. April 2 2009. http://www.concordcoalition.org/files/uploaded_for_nodes/docs/Iowa_Handout_final.pdf (accessed date: September 12, 2011).
38. The Henry J. Kaiser Family Foundation. Snapshots: Health Care Spending in the United States and Selected OECD Countries. April 2011. http://www.kff.org/insurance/snapshot/OECD042111.cfm (accessed September 12, 2011).
39. Centers for Medicare and Medicaid services. 2011 National health expenditure projections 2010-2020. http://www.cms.gov/NationalHealthExpendData/downloads/proj2010.pdf (accessed September 21, 2011).
40. U.S. Renal Data System, USRDS. 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. (accessed date: December 20, 2010). http://www.usrds.org/2010/ADR_booklet_2010_lowres.pdf, http://www.usrds.org/2009/pdf/V2_02_INC_PREV_09.PDF
41. St Peter WL. Introduction: Chronic kidney disease: A burgeoning health epidemic. J Manag Care Pharm. 2007; 13(9 Suppl D):S2-S5.
42. Ploth DW, Shepp PH, Counts C, Hutchison F. Prospective analysis of global costs for maintenance of patients with ESRD. Am J Kidney Dis. 2003; 42:12-21.
43. Burdick RA, Bragg-Gresham JL, Woods JD, etal. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2003; 63:2222-2229.
44. Cendoroglo Neto M, Manzano SI, Canziani ME, etal. Environmental transmission of hepatitis B and hepatitis C viruses within the hemodialysis unit. Artif Organs. 1995; 19:251-255.
45. Djordjević V, Stojanović K, Stojanović M, Stefanović V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs. 2000; 23:181-188.
46. Harmankaya O, Cetin B, Obek A, Seber E. Low prevalence of hepatitis C virus infection in hemodialysis units: Effect of isolation? Ren Fail. 2002; 24:639-644.
47. Mesjasz J, Wiecek A, Gonciarz Z, Mazur W, Kokot F. Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients? [Article in Polish]. Pol Merkur Lekarski. 2004; 16:362-367.
48. López L, López P, Arago A, etal. Risk factors for hepatitis B and C in multi-transfused patients in Uruguay. J Clin Virol. 2005; 34(Suppl 2):S69-S74.
49. Karkar A, Abdelrahman M, Ghacha R, Malik TQ. Prevention of viral transmission in HD units: The value of isolation. Saudi J Kidney Dis Transpl. 2006; 17:183-188.
50. Mohamed WZ. Prevention of hepatitis C virus in hemodialysis patients: Five years experience from a single center. Saudi J Kidney Dis Transpl. 2010; 21:548-554.
51. Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: Review of current international recommendations. Arab J Nephrol Transplant. 2011; 4:35-47.
52. Onuigbo M, Onuigbo NT. Economic Impact of Reduced HBV Testing Among Hemodialysis Patients in The New Environment of Bundling: Results of a Study of De Novo HBV Infection Rates in a Mayo Clinic Hemodialysis Population: A Call for Changes in Current US CDC Guidelines on HBV Testing Protocols. J Am Soc Nephrol. 2011; 22:815A. [SA-PO3028]. (Abstract).
53. Telaku S, Fejza H, Elezi Y, Bicaj T. Hepatitis B and C in dialysis units in Kosova. Virol J. 2009; 6:72.
54. Ferreira RC, Teles SA, Dias MA, etal. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: Prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz. 2006; 101:689-692.
55. Qadi AA, Tamim H, Ameen G, etal. Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods. Am J Infect Control. 2004; 32:493-495.
56. Chattopadhyay S, Rao S, Das BC, Singh NP, Kar P. Prevalence of transfusion-transmitted virus infection in patients on maintenance hemodialysis from New Delhi, India. Hemodial Int. 2005; 9:362-366.
57. Onuigbo M. Healthcare expenditure in the United States of America in the last year of life: Where ethics, medicine and economics collide? Int J Clin Pract. 2012; 66:226-227. doi: 10.1111/j.1742-1241.2011.02846.
58. Onuigbo MAC, Nesbit A, Weisenbeck J, Hurlburt J. Hepatitis B surface antigenemia following recombinant hepatitis B vaccine in an 81-year old ESRD patient on hemodialysis. Ren Fail. 2010; 32:531-532.